texas oncology more breakthroughs. more victories

In The News

Read more about what’s happening at Texas Oncology and the newest advancements in cancer care. Here are the latest Texas Oncology news and stories highlighting local practices and patients. Select a search option below by cancer center, physician, media type and year and click the search button to find your results. Items in yellow are articles and items in blue are videos.

Search Media Coverage

Is The Drug Elahere An Option When My Ovarian Cancer Returns?

Publication: SurvivorNet
08/21/2023
Noelle G. Cloven, M.D., Texas Oncology–Fort Worth Cancer Center was featured in a video on SurvivorNet discussing the ovarian cancer landscape. Dr. Cloven joined SurvivorNet and dove into the evolving ovarian cancer treatment space discussing topics from the latest guidance on PARP inhibitors, how the new drug Elahere is providing hope to cancer patients, folate receptor⁠–⁠alpha positive ovarian cancer, mirvetuximab soravtansine and more.

Central Texas Man Diagnosed with Skin Cancer Four Times in the Last Year

Publication: KVUE-TV (ABC, Austin)
08/04/2023
Since December 2022, Keith Westmoreland, patient of Christopher R. Oxner, M.D., FACS, USN, Texas Oncology Surgical Specialists-Austin Central, Cedar Park and South Austin, has been diagnosed with skin cancer four separate times, with two spots on his head and two on his chest. Both Keith and Dr. Oxner joined KVUE-TV (ABC, Austin) to discuss the risks of skin cancer, its symptoms and why this diagnosis is on the rise. In fact, incidence rates for melanoma have been rising rapidly over the past few decades, and in Texas, 4,998 cases of melanoma of the skin are expected in 2023, up 3.2% from 2022.

Managing An Ovarian Cancer Recurrence: How The New Drug Elahere Is Providing Hope

Publication: SurvivorNet
08/01/2023
Helen Dinkelspiel Eshed, M.D., Texas Oncology-Austin Central and South Austin was featured in various videos on SurvivorNet discussing the ovarian cancer landscape. Dr. Eshed joined SurvivorNet and dove into the evolving ovarian cancer treatment space discussing topics from the latest guidance on PARP inhibitors, how the new drug Elahere is providing hope to cancer patients, folate receptor⁠–⁠alpha positive ovarian cancer, mirvetuximab soravtansine and more.

Niraparib Maintenance Improves Survival in BRCA Wild-Type Ovarian Cancer

Publication: Targeted Oncology
08/01/2023
Robert L. Coleman, M.D., FACOG, FACS, Texas Oncology-The Woodlands spoke with Targeted Oncology about the NOVA trial, how it improves survival in BRCA wild-type ovarian cancer and the real-world findings from this trial, which evaluated second-line maintenance niraparib in patients with recurrent ovarian cancer.

The Four C’s for Balancing Cancer Treatment and the Classroom

Publication: Austin Medical Times, Houston Medical Times, Palestine Herald-Press, Pittsburg Gazette
08/01/2023

Heading back to school with all of the stresses that come with managing a cancer diagnosis is a daunting challenge. No matter if you’re a student or parental guardian of someone in school, learn how proper planning and support can help make it possible to create the right balance between successfully continuing one’s studies and undergoing cancer treatment.

Maintenance Therapy With Niraparib Prolongs PFS in Ovarian Cancer

Publication: Targeted Oncology
07/27/2023
Robert L. Coleman, M.D., FACOG, FACS, Texas Oncology-The Woodlands spoke with Targeted Oncology about the effect of maintenance therapy with niraparib on ovarian cancer. In the article, Dr. Coleman discusses the research he presented at ASCO, which found that niraparib (Zejula) as a maintenance therapy improved progression-free survival (PFS) in patients with newly diagnosed advanced ovarian cancer after first-line platinum-based chemotherapy, regardless of postoperative residual disease or biomarker status.

Texas Oncology Opens New, Expanded Comprehensive Cancer Center in Amarillo

Publication: Medical Construction & Design
07/19/2023

Texas Oncology has opened a new 50,000-square-foot cancer center in Amarillo, expanding the capacity of the practice to meet the growing need for cancer care in the Texas Panhandle region. The general design scheme was inspired by Amarillo’s unique landscape, and materials were selected for their visible texture and linearity to evoke the layers and strata visible in nearby Palo Duro Canyon.

West Veteran, Marathoner Describes Mentality During Immunotherapy Treatment for Melanoma

Publication: Waco Tribune-Herald
07/02/2023
David Mocio was diagnosed with stage 4 metastatic melanoma in 2015 and receives immunotherapy every 28 days. David spoke with the Waco Tribune-Herald saying he credits the treatment with saving his life, and studies have shown immunotherapy to be more effective than chemotherapy or radiation therapy against melanoma. Dr. Carlos Encarnacion, Texas Oncology-Hamilton and Horizon Circle shared with the outlet that immunotherapy is one of the biggest advancements in oncology in recent years, and the number of patients treated with immunotherapy has grown exponentially in the past decade.

Proton Therapy Benefits Prostate Cancer Treatment

Publication: Texas Monthly
07/01/2023

Men age 65 and older account for about 60% of all diagnosed prostate cancer cases. Proton therapy, an advanced form of radiation treatment, can treat new or recurrent prostate cancers with minimal exposure to healthy tissue. Texas Center for Proton Therapy offers a new imaging modality known as prostate-specific membrane antigen (PSMA) PET to detect this disease in the earlier stages.

How to Enjoy the Summer Foods of Texas and Lower Your Cancer Risk, Too

Publication: Austin Medical Times, Houston Medical Times
07/01/2023

For many people, summertime means firing up their grills and dusting off family-favorite summer recipes. To help Texans make healthy choices this summer, Athira Unnikrishnan, M.D., Texas Oncology–Austin Midtown, shares tips for mitigating cancer risks associated with grilled meats as well as examples of nutrient-rich, seasonal foods that contribute to overall health.